Hysteroscopic resection versus medical management of early pregnancy loss (HyME): a randomized controlled trial
EU CTIS ID: 2024-520166-63-00
What this study is testing
The aim of this trial is to compare primary hysteroscopic resection versus medical management of early miscarriages (< 10 weeks of gestation) in terms of efficacy, short and long-term complications, reproductive outcomes and patient satisfaction.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- EPL < 10 weeks of gestation
- Age ≥18 ≤ 50 years
- Signed informed consent
You likely can't join if
- Pregnancy of unknown location
- Severe bleeding requiring immediate surgical intervention
- Previous history of uterine surgery without proof of a normal cavity following the procedure
- Contra-indication to medical treatment including: Women who present with hemorrhage, hemodynamic instability, or signs of infection, Adrenal insufficiency, severe asthma.
- Women with severe anemia, bleeding disorders, or cardiovascular disease.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.